Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

Proteasome inhibitor (PI) carfilzomib (CFZ) has activity superior to bortezomib (BTZ) and is increasingly incorporated in multiple myeloma (MM) frontline therapy and relapsed settings. Most MM patients ultimately experience PI-refractory disease, an unmet medical need with poorly understood biology...

Descripción completa

Detalles Bibliográficos
Autores principales: Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808083/
https://www.ncbi.nlm.nih.gov/pubmed/28676669
http://dx.doi.org/10.1038/leu.2017.212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808083/
https://www.ncbi.nlm.nih.gov/pubmed/28676669
http://dx.doi.org/10.1038/leu.2017.212

Ejemplares similares